Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-SA01 nasal phage therapy for chronic rhinosinusitis with Staphylococcus aureus
ACTRN12616000002482Phase 2Completed
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Dec 2015
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AB-SA01 in chronic rhinosinusitis (CRS) and Staphylococcus aureus infection, sponsored by The Queen Elizabeth Hospital. Started Dec 2015; status: completed.
02
Drugs
AB-SA01
03
Conditions
chronic rhinosinusitis (CRS)Staphylococcus aureus infection
Beyond the preview
Go deeper on ACTRN12616000002482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000002482.